SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

The Cox regression analysis for time to hospital admission found that S gene-positive cases were associated with an increased risk of COVID-19 hospital admission: hazard ratio (HR) 1·85 (95% CI 1·39–2·47) when compared to S gene-negative cases, after adjusting for age, sex, deprivation, temporal tre...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:The Lancet (British edition) Ročník 397; číslo 10293; s. 2461 - 2462
Hlavní autori: Sheikh, Aziz, McMenamin, Jim, Taylor, Bob, Robertson, Chris
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Elsevier Ltd 26.06.2021
Elsevier Limited
Predmet:
Aged
Child
Child, Preschool
Coronaviruses
Correspondence
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 - virology
COVID-19 Vaccines
Demographics
Demography
Deprivation
Genes
Health surveillance
Humans
Immunization
Infections
Patient Admission - statistics & numerical data
Patient admissions
Polymerase chain reaction
Population Surveillance
Public health
Regression analysis
Risk
S gene
SARS-CoV-2 - genetics
SARS-CoV-2 - isolation & purification
Scotland - epidemiology
Severe acute respiratory syndrome coronavirus 2
Vaccination - statistics & numerical data
Vaccine efficacy
Vaccines
Scotland
United Kingdom > UK
ISSN:0140-6736, 1474-547X, 1474-547X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The Cox regression analysis for time to hospital admission found that S gene-positive cases were associated with an increased risk of COVID-19 hospital admission: hazard ratio (HR) 1·85 (95% CI 1·39–2·47) when compared to S gene-negative cases, after adjusting for age, sex, deprivation, temporal trend, and comorbidities. The corresponding hazard ratio for risk of hospital admission for S gene-positive cases was 0·38 (95% CI 0·24–0·58), with an interaction test p value of 0·19, suggesting that there was no evidence of a differential vaccine effect on hospital admissions among those first testing positive (appendix p 4). Considering the whole population cohort (rather than just hospital cases), the test-negative analysis to estimate vaccine effectiveness in preventing RT-PCR-confirmed SARS-CoV-2 infection showed that, compared to those unvaccinated, at least 14 days after the second dose, BNT162b2 (Pfizer–BioNTech vaccine) offered very good protection: 92% (95% CI 90–93) S gene-negative, 79% (75–82) S gene-positive.
Bibliografia:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
content type line 23
ISSN:0140-6736
1474-547X
1474-547X
DOI:10.1016/S0140-6736(21)01358-1